Beam Therapeutics (NasdaqGS:BEAM) reported positive Phase 1/2 data for its BEAM-302 program at a major international conference. The gene editing therapy showed durable restoration of alpha-1 ...
In the HiPEQ project, a consortium of industry and research partners has developed new laser-based approaches to enable ...
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Beam Therapeutics said Monday that it used ...
For first responders who answered the call that day, the artifact is a symbol of the damaged caused to the nation, and every ...
An (almost) real-life Holodeck for video calls.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results